Posted by admin on Jul 1st, 2022
SeaSpine (NASDAQ:SPNE – Get Rating) and Liquidia (NASDAQ:LQDA – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.
SeaSpine has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.
73.1% of SeaSpine shares are owned by institutional investors. Comparatively, 27.7% of Liquidia shares are owned by institutional investors. 9.3% of SeaSpine shares are owned by company insiders. Comparatively, 29.5% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares SeaSpine and Liquidia’s net margins, return on equity and return on assets.
This is a summary of recent ratings and recommmendations for SeaSpine and Liquidia, as reported by MarketBeat.
SeaSpine currently has a consensus price target of $32.83, indicating a potential upside of 481.12%. Liquidia has a consensus price target of $12.00, indicating a potential upside of 175.23%. Given SeaSpine’s stronger consensus rating and higher possible upside, equities analysts plainly believe SeaSpine is more favorable than Liquidia.
This table compares SeaSpine and Liquidia’s gross revenue, earnings per share (EPS) and valuation.
Liquidia has lower revenue, but higher earnings than SeaSpine. Liquidia is trading at a lower price-to-earnings ratio than SeaSpine, indicating that it is currently the more affordable of the two stocks.
SeaSpine beats Liquidia on 8 of the 14 factors compared between the two stocks.
SeaSpine Company Profile (Get Rating)
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Liquidia Company Profile (Get Rating)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.
Stelco (TSE:STLC) Receives New Coverage from Analysts at Stifel Nicolaus
Analyzing Leslie’s (NASDAQ:LESL) & High Tide (NASDAQ:HITI)